Last updated September 10, 2026
Key finding
HMS and NBS exhibited higher 24 h mean blood glucose values in comparison with DMS (p = 0.0001).
BL21 probiotic added to metformin in adults with type 2 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
BL21 probiotic added to metformin in adults with type 2 diabetes.
This study evaluated BL21 probiotic added to metformin in adults with type 2 diabetes.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
Yolanda A, Jorge LB, Carlos G, et al. Effects of Resistant Starch on Glycemic Control and Variability in Patients with Type 2 Diabetes. Nutrients. 2021;13(11):4052. doi:10.3390/nu13114052
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Digestible maize starch (DMS), High-amylose maize starch (HMS), Native banana starch (NBS) and Fasting Plasma Glucose (FPG), Indices of 24-hour glycemic variability, Blood glucose.
This study contributes evidence to
Primary intervention
Digestible maize starch (DMS)
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
6
Evidence pairs
886
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Digestible maize starch (DMS) → Fasting Plasma Glucose (FPG)
Digestible maize starch (DMS) → Fasting Plasma Glucose (FPG)
Digestible maize starch (DMS) → Indices of 24-hour glycemic variability
Digestible maize starch (DMS) → Indices of 24-hour glycemic variability
High-amylose maize starch (HMS) → Blood glucose
High-amylose maize starch (HMS) → Blood glucose
High-amylose maize starch (HMS) → Indices of 24-hour glycemic variability
High-amylose maize starch (HMS) → Indices of 24-hour glycemic variability
Native banana starch (NBS) → Indices of 24-hour glycemic variability
Native banana starch (NBS) → Indices of 24-hour glycemic variability
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Digestible maize starch (DMS) and Fasting Glucose, Digestible maize starch (DMS) and Indices of 24-hour glycemic variability.
This study contributes to the evidence on the following intervention-outcome relationships.
Diet and Nutrition
Diet and Nutrition
Curated evidence collections and hubs this study is part of.
All studies on Digestible maize starch (DMS)
Contributes to Digestible maize starch (DMS) evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies measuring Indices of 24-hour glycemic variability
Measures Indices of 24-hour glycemic variability as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Digestible maize starch (DMS) appears to improve fasting plasma glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Digestible maize starch (DMS) for indices of 24-hour glycemic variability.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Indices of 24-hour glycemic variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of High-amylose maize starch (HMS) for indices of 24-hour glycemic variability.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Indices of 24-hour glycemic variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Native banana starch (NBS) for indices of 24-hour glycemic variability.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Indices of 24-hour glycemic variability
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
